Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Nido Biosciences is raising $46,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Jamil Beg played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Nido Biosciences

Nido Biosciences is focusing on developing small molecule therapeutics for the treatment of neurodegenerative diseases. Nido is currently advancing two small molecule programs for genetically defined subpopulations of neurodegenerative diseases. The lead program, in-licensed from a top academic investigator, is focused on the treatment of a rare expansion repeat disease. In parallel to advancing these programs, Nido is building a best-in-class screening platform to enable identification of modulators of neurodegenerative disease biology using iPSC-derived neuronal cells from patients.

To learn more about Nido Biosciences, visit http://www.nidobio.com/

Contact:
Jamil Beg, President and Chief Executive Officer
857-305-1833
https://www.linkedin.com/in/jamilmbeg/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved